An experimental weight-loss drug that has not yet received regulatory approval is already attracting users willing to obtain unapproved versions online. Now, scientists are using artificial intelligence to investigate their experiences, uncovering unexpected symptom reports that differ from those documented in clinical trials.
The drug, retatrutide, belongs to a new generation of GLP-1 medications designed to help regulate appetite and body weight. Although it remains under investigation and is not approved for use, people are purchasing unapproved formulations that are not intended for human consumption and discussing their experiences on internet forums.
Source: ScienceDaily - AI — Read the full article on the original site ↗